Skip to content

Vascular Dysfunction in Offspring of Assisted Reproduction Technologies

Vascular Dysfunction in Offspring of Assisted Reproduction Technologies

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00837642
Enrollment
100
Registered
2009-02-05
Start date
2008-10-31
Completion date
2021-06-30
Last updated
2020-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Vascular function in offspring of ART

Brief summary

The prevalence of infertility has been estimated at 9% worldwide. The steadily increasing use of assisted reproductive technologies (ART) has allowed millions of infertile couples to have children. These children make up for 1 to 4% of the population in developed countries. ART involves the manipulation of early embryos at a time when they may be particularly vulnerable to external disturbances. In line with this concept, studies in mice suggest that ART alters the activity of enzymes involved in the regulation of metabolic and cardiovascular homeostasis. Alternatively, infertility itself or the drugs used to stimulate ovulation may have adverse effects on the outcome of the offspring. The safety of ART for long-term health is, therefore, of utmost importance. Among the potential long-term consequences of ART, cardiovascular disease may represent an important candidate, but there is no information. Investigators show that, children born after in vitro fertilization (IVF) present systemic and pulmonary vascular dysfunction at high-altitude when compared to age- and sex-matched control subjects. A 5 years follow-up study shows that premature vascular aegieng persist and evolve to arterial hypertension. Arterial hypertension may induce cardiac dysfunction. Therefore, the major goal of this proposal is to assess cardiac function in apparently healthy participants born after ART.

Interventions

DIAGNOSTIC_TESTTransthoracic echocardiography

Full transthoracic echocardiography will be performed.

Sponsors

University of Lausanne Hospitals
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Offspring of ART * Healthy * Born at term

Exclusion criteria

* Cardio-pulmonary malformations * Neuro-muscular malformations

Design outcomes

Primary

MeasureTime frameDescription
Cardiac function1 yearEjection fraction \[%\]

Secondary

MeasureTime frameDescription
Left ventricular musce mass1 yearLeft ventricular muscle mass \[g/m2\]

Countries

Switzerland

Contacts

Primary ContactUrs Scherrer, Prof
Urs.Scherrer2@insel.ch+4131 632 2111
Backup ContactEmrush Rexhaj, PD
emrush.rexhaj@insel.ch+4131 632 2111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026